Amgen CEO Robert Bradway Sells Shares for Tax Withholding Amid Stock Volatility

Robert A. Bradway, chairman and CEO of Amgen Inc. (NASDAQ: AMGN), filed two Form 4 transactions on May 2 and May 7 to cover tax withholding on stock-based compensation such as RSUs. On May 2, he sold approximately 5,057 shares at about $329.82 per share, and on May 7 he sold 2,079 shares at around $331.11 per share. These sales generated roughly $1.7 million and $700,000 in proceeds, respectively—equivalent to about KRW 2.5 billion and KRW 1 billion—for tax purposes. Despite these dispositions, Bradway still directly holds around 500,000 shares. Disclosures show he also retains indirect holdings through a GRAT and accounts in his spouse’s name, as well as dividend equivalents linked to unvested RSUs.

Earlier this month, Amgen reported its first-quarter 2026 results and, buoyed by revenue growth, raised its full-year guidance. However, the stock has exhibited increased volatility, spiking around the earnings release before undergoing a correction.

Headquartered in Thousand Oaks, California, Amgen is a leading biopharmaceutical company with a portfolio of therapies for serious diseases—rheumatoid arthritis, psoriasis, osteoporosis, cardiovascular disease and cancer—placing it among global “big-pharma–level” biotechs. Bradway has served as Amgen’s CEO since 2012 and, as one of its longest-tenured chief executives, holds the dual roles of board chairman and CEO, steering company strategy and pipeline expansion.